Exelixis opened higher at $68.28, compared with its previous close of $66.20. In the last trading session, the stock traded between $67.05 and $72.10. It showed an upward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Exelixis is now worth
$ 333.05
giving a profit of
$ 233.05 (233.05%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 13 Analysts
Buy
30.77%
Hold
61.54%
Sell
7.69%
Markets Today
Today's Change
+$5.44 (+8.22%)
Day High
$72.10
Day Low
$67.05
Day Open
$68.28
Prev Close
$66.20
Volume
15,70,533
1W Return
9.70%
1M Return
22.06%
3M Return
29.59%
6M Return
60.30%
1Y Return
81.69%
Fundamentals
Market Cap ($ Mn)
17,751
PE Ratio
17.17
PB Ratio
7.35
PEG Ratio
0.28
ROE
36.46%
ROCE
35.70%
EPS (TTM)
$0.85
Investment Returns
1 Week
9.70%
1 Month
22.06%
3 Months
29.59%
6 Months
60.30%
9 Months
69.44%
Financials
Quarterly
All values in $ Mn
555.4
Mar 25
568.3
Jun 25
597.8
Sep 25
598.7
Dec 25
610.8
Mar 26
628.7
Jun 26
Updates
19Oct
Citizens raises Exelixis price target to $65, maintains Outperform
Citizens analyst Silvan Turkcan raised Exelixis' price target from $55 to $65. The analyst maintained a Market Outperform rating on the stock. The price target increase represents a $10 uplift from the previous level.
11 days ago
16Oct
Exelixis to release Q3FY26 results on Oct 29, 2026
Exelixis, Inc. will release Q3 2026 financial results on October 29, 2026. Conference call scheduled for 5:00 pm ET / 2:00 pm PT following the release. Webcast replay will be archived on the company website for one year.
14 days ago
11Sep
Exelixis FDA review extended for zanzalintinib colorectal cancer application
Exelixis receives three-month FDA review extension for zanzalintinib combo. New PDUFA action date set for March 3, 2027. Submission classified as major amendment by FDA. Update addresses safety and efficacy data request.
1mo ago
1Sep
Exelixis wins patent appeal, blocks generic launch until 2030
U.S. Court of Appeals affirms 2024 judgment favoring Exelixis against MSN Laboratories. Three patents covering crystalline malate salt of cabozantinib upheld as valid. Generic launch delayed to January 15, 2030, pending further legal outcomes. Appeal regarding low-impurity formulation patent dismissed as moot.
1mo ago
20Aug
Kuehn Law joins Exelixis probe over fiduciary duty and self-dealing
Kuehn Law joins SBS Law and Levi & Korsinsky in probing Exelixis Inc. The new inquiry focuses on fiduciary breaches and self-dealing, while existing probes target Q2 revenue misses and guidance cuts. Investors are urged to contact firms regarding potential claims.
2mo ago
30Jul
Kuehn Law investigates Exelixis for potential self-dealing
Kuehn Law, PLLC has launched an investigation into Exelixis, Inc. regarding alleged breaches of fiduciary duty and self-dealing by its officers and directors. The firm asserts that shareholders may recover damages and secure governance reforms. Investors are urged to contact the firm promptly due to potential deadlines for enforcing rights.
